139 related articles for article (PubMed ID: 36651179)
1. Design of Analgesic Trivalent Peptides with Low Withdrawal Symptoms: Probing the Antinociceptive Profile of Novel Linear and Cyclic Peptides as Opioid Pan Ligands.
Stefanucci A; Minosi P; Pieretti S; Tanguturi P; Molnar G; Scioli G; Marinaccio L; Della Valle A; Streicher JM; Mollica A
ACS Chem Neurosci; 2023 Feb; 14(3):506-515. PubMed ID: 36651179
[TBL] [Abstract][Full Text] [Related]
2. Antinociceptive profile of potent opioid peptide AM94, a fluorinated analogue of biphalin with non-hydrazine linker.
Mollica A; Costante R; Stefanucci A; Pinnen F; Lucente G; Fidanza S; Pieretti S
J Pept Sci; 2013 Apr; 19(4):233-9. PubMed ID: 23136069
[TBL] [Abstract][Full Text] [Related]
3. Potent, Efficacious, and Stable Cyclic Opioid Peptides with Long Lasting Antinociceptive Effect after Peripheral Administration.
Stefanucci A; Dimmito MP; Macedonio G; Ciarlo L; Pieretti S; Novellino E; Lei W; Barlow D; Houseknecht KL; Streicher JM; Mollica A
J Med Chem; 2020 Mar; 63(5):2673-2687. PubMed ID: 31834798
[TBL] [Abstract][Full Text] [Related]
4. Identification and Pharmacological Characterization of a Low-Liability Antinociceptive Bifunctional MOR/DOR Cyclic Peptide.
Li Y; Eans SO; Ganno-Sherwood M; Eliasof A; Houghten RA; McLaughlin JP
Molecules; 2023 Nov; 28(22):. PubMed ID: 38005269
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo activity of cyclopeptide Dmt-c[d-Lys-Phe-Asp]NH
Gach-Janczak K; Piekielna-Ciesielska J; Adamska-Bartłomiejczyk A; Wtorek K; Ferrari F; Calo' G; Szymaszkiewicz A; Piasecka-Zelga J; Janecka A
Peptides; 2018 Jul; 105():51-57. PubMed ID: 29684591
[TBL] [Abstract][Full Text] [Related]
6. Antinociceptive Efficacy of the µ-Opioid/Nociceptin Peptide-Based Hybrid KGNOP1 in Inflammatory Pain without Rewarding Effects in Mice: An Experimental Assessment and Molecular Docking.
Dumitrascuta M; Bermudez M; Trovato O; De Neve J; Ballet S; Wolber G; Spetea M
Molecules; 2021 May; 26(11):. PubMed ID: 34071603
[TBL] [Abstract][Full Text] [Related]
7. Structure-Activity Relationships of a Novel Cyclic Hexapeptide That Exhibits Multifunctional Opioid Agonism and Produces Potent Antinociceptive Activity.
Zhang Q; Xu B; Chen D; Wu S; Hu X; Zhang X; Yu B; Zhang S; Yang Z; Zhang M; Fang Q
J Med Chem; 2024 Jan; 67(1):272-288. PubMed ID: 38118143
[TBL] [Abstract][Full Text] [Related]
8. Translation of structure-activity relationships from cyclic mixed efficacy opioid peptides to linear analogues.
Anand JP; Porter-Barrus VR; Waldschmidt HV; Yeomans L; Pogozheva ID; Traynor JR; Mosberg HI
Biopolymers; 2014 Jan; 102(1):107-14. PubMed ID: 24436042
[TBL] [Abstract][Full Text] [Related]
9. Discovery of Novel Multifunctional Ligands with μ/δ Opioid Agonist/Neurokinin-1 (NK1) Antagonist Activities for the Treatment of Pain.
Giri AK; Apostol CR; Wang Y; Forte BL; Largent-Milnes TM; Davis P; Rankin D; Molnar G; Olson KM; Porreca F; Vanderah TW; Hruby VJ
J Med Chem; 2015 Nov; 58(21):8573-83. PubMed ID: 26465170
[TBL] [Abstract][Full Text] [Related]
10. Opioid peptidomimetics: leads for the design of bioavailable mixed efficacy μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands.
Mosberg HI; Yeomans L; Harland AA; Bender AM; Sobczyk-Kojiro K; Anand JP; Clark MJ; Jutkiewicz EM; Traynor JR
J Med Chem; 2013 Mar; 56(5):2139-49. PubMed ID: 23419026
[TBL] [Abstract][Full Text] [Related]
11. Endogenous opioid peptides contribute to antinociceptive potency of intrathecal [Dmt1]DALDA.
Szeto HH; Soong Y; Wu D; Qian X; Zhao GM
J Pharmacol Exp Ther; 2003 May; 305(2):696-702. PubMed ID: 12606628
[TBL] [Abstract][Full Text] [Related]
12. Bis-Cyclic Guanidine Heterocyclic Peptidomimetics as Opioid Ligands with Mixed μ-, κ- and δ-Opioid Receptor Interactions: A Potential Approach to Novel Analgesics.
McLaughlin JP; Rayala R; Bunnell AJ; Tantak MP; Eans SO; Nefzi K; Ganno ML; Dooley CT; Nefzi A
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077029
[TBL] [Abstract][Full Text] [Related]
13. Cyclic biphalin analogues with a novel linker lead to potent agonist activities at mu, delta, and kappa opioid receptors.
Remesic M; Macedonio G; Mollica A; Porreca F; Hruby V; Lee YS
Bioorg Med Chem; 2018 Jul; 26(12):3664-3667. PubMed ID: 29858157
[TBL] [Abstract][Full Text] [Related]
14. Opioid peptide-derived analgesics.
Schiller PW
AAPS J; 2005 Oct; 7(3):E560-5. PubMed ID: 16353933
[TBL] [Abstract][Full Text] [Related]
15. Peptide-derived ligands for the discovery of safer opioid analgesics.
Eliasof A; Liu-Chen LY; Li Y
Drug Discov Today; 2024 May; 29(5):103950. PubMed ID: 38514040
[TBL] [Abstract][Full Text] [Related]
16. Discovery of 3-((dimethylamino)methyl)-4-hydroxy-4-(3-methoxyphenyl)-N-phenylpiperidine-1-carboxamide as novel potent analgesic.
Huang H; Wang W; Xu X; Zhu C; Wang Y; Liu J; Li W; Fu W
Eur J Med Chem; 2020 Mar; 189():112070. PubMed ID: 31982651
[TBL] [Abstract][Full Text] [Related]
17. The behavioral effects of a mixed efficacy antinociceptive peptide, VRP26, following chronic administration in mice.
Anand JP; Boyer BT; Mosberg HI; Jutkiewicz EM
Psychopharmacology (Berl); 2016 Jul; 233(13):2479-87. PubMed ID: 27117141
[TBL] [Abstract][Full Text] [Related]
18. Development of novel LP1-based analogues with enhanced delta opioid receptor profile.
Pasquinucci L; Turnaturi R; Prezzavento O; Arena E; Aricò G; Georgoussi Z; Parenti R; Cantarella G; Parenti C
Bioorg Med Chem; 2017 Sep; 25(17):4745-4752. PubMed ID: 28734666
[TBL] [Abstract][Full Text] [Related]
19. Bioactivity of new mu and delta opioid peptides.
Capasso A
Med Chem; 2007 Sep; 3(5):480-7. PubMed ID: 17897075
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of mixed MOR/KOR efficacy cyclic opioid peptide analogs with antinociceptive activity after systemic administration.
Perlikowska R; Piekielna J; Gentilucci L; De Marco R; Cerlesi MC; Calo G; Artali R; Tömböly C; Kluczyk A; Janecka A
Eur J Med Chem; 2016 Feb; 109():276-86. PubMed ID: 26785295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
